GlassScriptPhysician profile
Jayne S Fortson
NPI 1932170297
$12,733.29
in general payments reported to CMS, 2019-2025
29 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,631 · 2020: $527 · 2021: $322 · 2022: $1,241 · 2023: $2,440 · 2024: $2,897 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,699 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,699.13 |
| Education | $314.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,555.02 | 2019-2025 | |
| Janssen Biotech, INC. | $1,672.50 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,513.48 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $993.74 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $903.05 | 2019-2025 | |
| Amgen INC. | $850.91 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $670.30 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $465.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $400.90 | 2022-2025 | Sotyktu |
| Celgene Corporation | $256.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $225.08 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $221.88 | 2023-2025 | Zoryve |
| Dermira, INC. | $161.01 | 2019-2020 | |
| Genzyme Corporation | $128.79 | 2019-2025 | |
| Incyte Corporation | $128.52 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $117.89 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $95.68 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.44 | 2023 | Cyltezo |
| Leo Pharma INC. | $49.04 | 2024-2025 | Anzupgo, Adbry |
| Allergan, INC. | $48.62 | 2019 | |
| Merz North America, INC. | $34.25 | 2022 | |
| Organon LLC | $30.88 | 2025 | Vtama |
| Organogenesis INC. | $23.50 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $23.43 | 2019 | |
| Sandoz INC. | $22.72 | 2023 | Hyrimoz |
| Helsinn Therapeutics (U.S.), INC. | $20.65 | 2019 | |
| Biofrontera INC. | $18.00 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.53 | 2019 | |
| Strata Skin Sciences, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Fortson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.